Recent Updates
Recently added Catalysts
REGN

Regeneron Announces Presentation at the 25th Annual Credit Suisse Healthcare Conference

Key Takeaway: Regeneron Announces Presentation at the 25th Annual Credit Suisse Healthcare Conference

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y.,Oct. 21, 2016/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast its presentation at the 25thAnnual Credit Suisse Healthcare Conference at10:00 a.m. ETonTuesday, November 8, 2016.
The session may be accessed through the Company's web site,www.regeneron.com, on the 'Events and Presentations' page.  Archived versions of the presentations will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ:REGN) is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, oncology, and infectious diseases. For additional information about the company, please visitwww.regeneron.comor follow @Regeneron on Twitter.
Contact Information:
Investor Relations Corporate Communications
Manisha Narasimhan, Ph.D. Hala Mirza
914.847.5126 914.847.3422
[email protected] [email protected]
Last updated: Oct 21, 2016